Aurobindo Pharma Limited

Informe acción NSEI:AUROPHARMA

Capitalización de mercado: ₹717.5b

Aurobindo Pharma Dividendos y recompras

Dividendo controles de criterios 2/6

Aurobindo Pharma es una empresa que paga dividendos con una rentabilidad actual de 0.24% que está bien cubierta por los beneficios.

Información clave

0.2%

Rentabilidad por dividendo

1.3%

Rendimiento de la recompra

Rendimiento total para el accionista1.5%
Rendimiento futuro de los dividendos0.4%
Crecimiento de los dividendos4.8%
Próxima fecha de pago de dividendosn/a
Fecha ex dividendon/a
Dividendo por acción₹3.000
Ratio de pago2%

Últimas actualizaciones de dividendos y recompras

Recent updates

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Nov 12
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Oct 20
Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Sep 10
Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23
This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Aug 13
Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29
Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 07
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Jun 14
Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

May 21
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Feb 11
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Jan 09
Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Nov 02
Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Jun 20
We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: El pago de dividendos de AUROPHARMA ha sido volátil en los últimos 10 años.

Dividendo creciente: El pago de dividendos de AUROPHARMA ha aumentado en los últimos 10 años.


Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Aurobindo Pharma vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de AUROPHARMA con la del mercado?
SegmentoRentabilidad por dividendo
Empresa (AUROPHARMA)0.2%
Suelo de mercado 25% (IN)0.2%
Techo de mercado 25% (IN)1.2%
Media de la industria (Pharmaceuticals)0.7%
Analista de previsiones (AUROPHARMA) (hasta 3 años)0.4%

Dividendo destacado: El dividendo de AUROPHARMA(0.24%) no es notable en comparación con el 25% inferior de pagadores de dividendos del mercado Indian (0.25%).

Alto dividendo: El (0.24%) del dividendo de AUROPHARMA es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado Indian (1.15%).


Pago de beneficios a los accionistas

Cobertura de los beneficios: Con su bajo ratio de pago (2.4%), los pagos de dividendos de AUROPHARMA están totalmente cubiertos por los beneficios.


Pago en efectivo a los accionistas

Cobertura de flujo de caja: AUROPHARMA está pagando dividendo pero la empresa no tiene flujos de caja libre.


Descubre empresas que pagan buenos dividendos